麻豆传媒

Novo Nordisk was ordered to pay nearly $60 million following a regarding illegal off-label marketing and downplaying the risks of their type 2 diabetes drug liraglutide (Victoza). (Markets Insider)

The FDA issued a warning that patients shouldn't a potassium-lowering drug, at the same time as other oral medications, because it can inhibit their efficacy. Instead, those drugs should be taken 3 hours before or after the hyperkalemia treatment.

Two pharmaceutical lobbying groups -- the Pharmaceutical Research and Manufacturers of America (PhRMA) and the Biotechnology Innovation Organization (BIO) -- are testing Nevada's in court, arguing it violates the Constitution. The went into effect this past June. (The Nevada Independent, Business Insider)

The Juvenile Diabetes Research Foundation (JDRF) has partnered with India-based pharmaceutical company Biocon to test the safety of their oral insulin treatment, . (Diabetes.co.uk)

A may not only lengthen lifespan, but may also improve overall strength, a new mouse study found. "We expected some differences, but I was impressed by the magnitude we observed -- a 13% increase in median life span for the mice on a high fat vs high carb diet. In humans, that would be seven to 10 years. But equally important, those mice retained quality of health in later life," senior author Jon Ramsey, PhD, of the University of California Davis, said in a press release. (Cell Metabolism)

Consumers should be wary of using apps as part of , a new study warned, citing insufficient oversight that may lead to poor reliability and quality. Researchers ranked Tactio Health: My Connected Health Logbook for iOS devices and American Association of Diabetes Educators Diabetes Goal Tracker for Android devices as two of the top diabetes apps currently available. (Reuters)

Following the recent popularity growth of insulin pumps, a new report is predicting the could reach nearly $10 billion by 2025. (The Global Health News)

Comment